Bianca Menchicchi

Bianca Menchicchi

Auto-generated profile, based on publicly available information

Bianca Menchicchi

School of Science, University of Navarra

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2014 in Biomacromolecules
Verified
Journal Article
Closed access
BMB. Menchicchi
B. Menchicchi
JFJ. P. Fuenzalida
J. P. Fuenzalida
KBKishore Babu Bobbili
Kishore Babu Bobbili
AHA. Hensel
A. Hensel
MSMusti J. Swamy
Musti J. Swamy
Francisco M. GoycooleaFrancisco M. Goycoolea
Francisco M. Goycoolea

18 February 2015 in Biomacromolecules
Verified
Journal Article
Closed access
BMB. Menchicchi
B. Menchicchi
JFJ. P. Fuenzalida
J. P. Fuenzalida
AHA. Hensel
A. Hensel
MSM. J. Swamy
M. J. Swamy
LDL. David
L. David
Francisco M. GoycooleaFrancisco M. Goycoolea
Francisco M. Goycoolea

5 April 2017 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PDF file
Alan MackieAlan Mackie
Alan Mackie
Francisco M. GoycooleaFrancisco M. Goycoolea
Francisco M. Goycoolea
BMBianca Menchicchi
Bianca Menchicchi
Carla Marcella CaramellaCarla Marcella Caramella
Carla Marcella Caramella
FSFrancesca Saporito
Francesca Saporito
LMLuciano Marcelloni
Luciano Marcelloni

8 May 2012 in Colloid and Polymer Science
Verified
Journal Article
Closed access
PDF file
Francisco M. GoycooleaFrancisco M. Goycoolea
Francisco M. Goycoolea
AVAngela Valle-Gallego
Angela Valle-Gallego
RSRossana Stefani
Rossana Stefani
BMBianca Menchicchi
Bianca Menchicchi
LDLaurent David
Laurent David
MAMaría J. Alonso
María J. Alonso

29 October 2015 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
BMBianca Menchicchi
Bianca Menchicchi
AHAndreas Hensel
Andreas Hensel
Francisco M. GoycooleaFrancisco M. Goycoolea
Francisco M. Goycoolea
The standard eradication treatment of the hostile Helicobacter pylori (H. pylori) stomach infection is facing increasing alarming antibiotic resistance worldwide and calls for alternative strategies to the use of antibiotics. One new perspective in this direction is cytoprotective compounds for targeted prevention of the adhesion of the bacteria to the stomach host cell and to inhibit the bacterial cell-cell communication via quorum sensing by specific inhibitors. Bacterial adhesion of H. pylori to the host cells is mainly mediated by carbohydrate-protein interactions. Therefore, the use of polyvalent carbohydrates, (e.g. plant-derived polysaccharides), as potential antiadhesive compounds, seems to be a promising tool to prevent the initial docking of the bacterium to the stomach cells. Polysaccharides are common constituents of daily food, either as starch or as dietary fiber and often also function as excipients for galenic drug-delivery formulations. In addition, polysaccharides with defined pharmacodynamics action against bacterial outer membrane proteins can have potential as therapeutic tools in the treatment of bacterial infections. Some polysaccharides are known to possess antibacterial properties against gram-positive bacteria, others to inhibit bacterial colonization by blocking specific carbohydrate receptors involved in host-bacteria interaction. This mode of action is advocated as alternative antiadhesion therapy. Ongoing research is also seeking for polysaccharide-based nanoformulations with potential for local drug delivery at the stomach as novel H. pylori therapies. These approaches pose challenges concerned with the stability of the nanomaterials in the harsh conditions of the gastric environment and their capacity to adhere to the stomach mucosa. In a global scenario, geographical diversity and social habits, namely lifestyle and dietary factors, influence the prevalence of the H. pylori-associated diseases and their severity. In this context, the exploration of the biological activity of plant-derived products or polysaccharides commonly present in foods is increasingly becoming more and more attractive. This review aims to present the current state-of-the-art on the antiadhesive capacity of different polysaccharide families, on polysaccharide-based nanosystems and the proof-of-concept evidence of their potential use as alternative medicines against H. pylori.

1 November 2013 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
GMGuillermo Marcial
Guillermo Marcial
JMJutta Messing
Jutta Messing
BMBianca Menchicchi
Bianca Menchicchi
Francisco M. GoycooleaFrancisco M. Goycoolea
Francisco M. Goycoolea
GFGerhard Faller
Gerhard Faller
AHAndreas Hensel
Andreas Hensel
EPS1190 was isolated from skim milk fermented with Stretococcus thermophilus CRL1190. The polysaccharide consisted of 33% glucose and 66% galactose with 1,4- and 1,4,6-galactose residues as main building blocks beside a high amount of 1,4-linked glucose. The polymer was characterized additionally concerning viscosity and zeta potential. EPS1190 stimulated cellular vitality and proliferation of human stomach AGS cells and human buccal KB cells significantly. EPS1190 stimulated phagocytosis rate of murine macrophages RAW264.7 significantly. NO-release or anti-inflammatory effects by inhibition of LPS-induced NO release were not observed. Confocal laser scanning microscopy revealed that EPS1190 is partially internalized into AGS cells via endosomes. The bioadhesive absorption of FITC-labeled EPS1190 into the mucus layer on the apical side of the epithelium using histological tissue sections from human stomach was observed. Specific interaction of EPS1190 with mucin can be excluded as shown by microviscosimetry studies. EPS1190 increased the adhesion of H. pylori to AGS cells, which resulted in increased secretion of proinflammatory cytokines TNFa, IL-6 and IL-8. Summarizing, EPS1190 seems to stimulate epithelial cell regeneration and immunological innate defense mechanisms, which again can rationalized the use of this polysaccharide as cytoprotective compound in probiotioc preparations.